( evels as well as thereactive rise of p...)Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur,Health

evels as well as the reactive rise of plasma renin, may therefore achieve a better protection from adverse cardiovascular events in early morning hours. This is crucial if one considers that myocardial infarction is three times more likely to begin in the morning than during night time and that morning hypertension has been identified as the strongest independent risk factor for stroke.

Another remaining major problem of current hypertension therapy is the lack of patient compliance. More than 50% of all patients who initiate oral drug therapy either completely discontinue treatment within the first 12 months or take their drugs only partially in-line with their doctor’s guidance. A physician administered vaccine would no longer require daily self-medication by the patient. The observed half-life of the vaccine-induced antibodies suggests a treatment regimen with booster injections every four to six months. In between these periods of time, the patient is no longer burdened with daily drug therapy. These advantages should allow for a better overall control of
hypertension, which is today the leading risk factor for mortality in the world.”

About early morning blood pressure
Blood pressure is not static but undergoes natural variations which follow a circadian pattern. Highest levels are reached during the morning, which then decline to reach a trough value at about midnight. In the early morning, a steep increase in blood pressure occurs. It has been suggested that this morning surge in blood pressure triggers adverse cardiovascular events. Each year in the United States alone acute myocardial infarction develops in over 600,000 persons who were previously free of cardiac symptoms. A large study has revealed a marked circadian periodicity in the onset of myocardial infarction with the primary peak incidence being in the morning. At this time, myocardial
infarction is three times as likely to onset as during the
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine